Tezepelumab Reduces Alarmin Cytokine Levels in Upper Airway Epithelial Cells in Patients With Severe Asthma
Clinical & Experimental Allergy · 2026-07 · 56 (7) · 830-832
DOI: 10.1111/cea.70294 ↗At a glance
Journal article in Clinical & Experimental Allergy, published online on 2026-03-27. Written by Hazel Marriott and 3 co-authors. Institution: Alberta Respiratory Centre, Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. Cited 2 times so far (Crossref); 9 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AstraZeneca Canada.
Abstract (original language)
Nasal epithelial cell alarmin cytokine levels are reduced in patients with severe asthma following tezepelumab. This is the first report showing nasal alarmin cytokine protein expression depletion following biologics.
Authors and institutions
- Alberta Respiratory Centre, Division of Pulmonary Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
- Bagchi School of Public Health, Ahmedabad University, Ahmedabad, Gujarat, India.
ORCID profiles: Subhabrata Moitra, Paige Lacy
Funding
- AstraZeneca Canada
Cite
APA
Marriott, H., Adatia, A., Moitra, S., & Lacy, P. (2026). Tezepelumab Reduces Alarmin Cytokine Levels in Upper Airway Epithelial Cells in Patients With Severe Asthma. Clinical & Experimental Allergy, 56(7), 830-832. https://doi.org/10.1111/cea.70294
Vancouver
Marriott H, Adatia A, Moitra S, Lacy P. Tezepelumab Reduces Alarmin Cytokine Levels in Upper Airway Epithelial Cells in Patients With Severe Asthma. Clinical & Experimental Allergy. 2026;56(7):830-832. doi:10.1111/cea.70294
BibTeX
@article{Marriott2026,
author = {Marriott, Hazel and Adatia, Adil and Moitra, Subhabrata and Lacy, Paige},
title = {Tezepelumab Reduces Alarmin Cytokine Levels in Upper Airway Epithelial Cells in Patients With Severe Asthma},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {7},
pages = {830--832},
doi = {10.1111/cea.70294}
}
EUVIMED